Effects of miglitol, acarbose, and sitagliptin on plasma insulin and gut peptides in type 2 diabetes mellitus: a crossover study
New obesity drug boosts GLP-1 weight loss without added side effects A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy without adding side effects in a mid-stage clinical trial, pointing to a powerful new combination approach to tackling obesity
If you experience new or worsening anxiety, low mood, or suicidal thoughts, seek urgent medical help and inform your GP immediately
doi:10.1038/s41598-021-93916-z
Many years later, the first FDA-approved study on MDMA in human subjects occurred in 1992
Make sure to order your new prescription in time so you do not miss your next dose